Moderna (MRNA) EBIT (2017 - 2026)

Moderna (MRNA) has reported EBIT for 10 consecutive years, with -$815.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 10.14% year-over-year to -$815.0 million in Q2 2026; TTM through Jun 2026 was -$3.3 billion, a 1.44% decrease from a year earlier, with the FY2025 full-year figure at -$3.1 billion, up 22.08% from the prior year.
• EBIT was -$815.0 million for Q2 2026 at Moderna, up from -$1.4 billion in the prior quarter.
• Over five years, EBIT peaked at $4.2 billion in Q1 2022 and troughed at -$2.0 billion in Q3 2023.
• A 5-year average of -$224.5 million and a median of -$836.0 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 233.89% in 2022 and tumbled 20866.67% in 2024, its largest moves.
• Over 5 years, EBIT stood at $1.6 billion in 2022, then sank by 99.62% to $6.0 million in 2023, then plunged by 20866.67% to -$1.2 billion in 2024, then soared by 31.22% to -$857.0 million in 2025, then increased by 4.9% to -$815.0 million in 2026.
• The last three EBIT figures came in at -$815.0 million (Q2 2026), -$1.4 billion (Q1 2026), and -$857.0 million (Q4 2025), per Business Quant data.